Checkmate 9kd Arm B Final Analysis: Efficacy And Safety Of Nivolumab Plus Docetaxel For Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer.

Karim Fizazi,Pablo González Mella,Daniel Castellano,Jose Nicolas Minatta,Arash Rezazadeh,David R. Shaffer,Juan Carlos Vazquez Limon, Héctor Manuel Sánchez López,Andrew J. Armstrong,Lisa Horvath,Carlos Dzik,Neha P. Amin,Jia Li,Keziban Unsal-Kacmaz,Margitta Retz,Fred Saad,Daniel Peter Petrylak,Russell Kent Pachynski

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 11|浏览35

暂无评分

摘要

12Background: CheckMate 9KD (NCT03338790) is a phase 2 trial of nivolumab (NIVO; anti-PD-1) in combination with rucaparib, docetaxel (DOCE), or enzalutamide for patients with metastatic castration-...

查看译文

关键词

Enzalutamide,Docetaxel,Nivolumab,Rucaparib,Prostate cancer,Castration,Oncology,Checkmate,Medicine,Chemotherapy naive,Internal medicine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要